Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 18/20 | 0.55 |
| ▸ | S1PR3 | Q99500 | 9/20 | 0.55 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.48 |
| ▸ | MINK1 | Q8N4C8 | 2/20 | 0.48 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.48 |
| ▸ | MARK3 | P27448 | 1/20 | 0.48 |
| ▸ | PLK1 | P53350 | 1/20 | 0.48 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3070539 | 0.84 | S1PR1 (0.58) | S1PR1S1PR3MAP4K4MINK1KCNH2 | |
| SCHEMBL2998264 | 0.82 | S1PR1 (0.62) | S1PR1S1PR3MAP4K4MINK1KCNH2 | |
| SCHEMBL3057688 | 0.78 | S1PR1 (0.71) | S1PR1S1PR3MAP4K4MINK1 | |
| SCHEMBL2989163 | 0.75 | S1PR1 (0.60) | S1PR1S1PR3MAP4K4MINK1KCNH2 | |
| SCHEMBL2993963 | 0.75 | S1PR1 (0.57) | S1PR1S1PR3MAP4K4MINK1KCNH2 | |
| SCHEMBL1965044 | 0.75 | S1PR1 (0.66) | S1PR1S1PR3MAP4K4MINK1DYRK3 | |
| SCHEMBL13045463 | 0.74 | S1PR1 (0.75) | S1PR1S1PR3MAP4K4MINK1 | |
| SCHEMBL10455334 | 0.73 | S1PR1 (0.62) | S1PR1S1PR3MAP4K4MINK1KCNH2 | |
| SCHEMBL2989389 | 0.73 | S1PR1 (0.84) | S1PR1S1PR3MAP4K4MINK1 | |
| SCHEMBL2993956 | 0.73 | S1PR1 (0.63) | S1PR1S1PR3MAP4K4MINK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100273771-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (SIP) | GLAXO GROUP LIMITED (GB) | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273771-A1 | OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (SIP) | S1PR3, S1PR1, S1PR2 | S1PR1 2/4885S1PR3 1/4885MAP4K4 1850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.